Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Amicus Therapeutics hat Freitag nachbörslich die FDA Zulassuzng für Migalastat (Galafold) erhalten Auch die jüngst veröffentlichten Quartalszahlen sind positiv ausgefallen. In Q2 erzielte man ein EPS von -$0.33 und lag damit Inline. Positiv fielen allerdings die Umsätze auf. Man erzielte $21.3M und übertraf damit den Analystenkonsens von $19.16M. Auch beim Ausblick konnte man punkten. Die...
Lets take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly...
BioMarin Pharmaceutical said on ?Friday it would acquire Amicus ?Therapeutics ?for about $4.8 ?billion, expanding its presence in rare metabolic diseases.
The consensus price target hints at a 60.6% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective,...
